Lupin’s Nagpur facility receives Establishment Investigation Report (EIR) from US FDA

Deepthi | Myequity news | Date : 24-08-2018 18:30:00 IST

Pharma major Lupin Limited (Lupin) announced that it has received the Establishment Investigation Report (EIR) from US FDA for the successful inspection of its Nagpur facility. The inspection was conducted in May 2018.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards.”

About Lupin Limited:

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (301h June 2018, Bloomberg) and revenues (31" March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31' March 2018, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively.


More from Myequity